Possible Role and Therapeutic Target of PDGF-D Signalling in Colorectal Cancer.
| Autor: | Olsen RS; a Department of Laboratory Medicine, Division of Medical Diagnostics , Region Jönköping County , Jönköping , Sweden.; b Division of Drug Research, Department of Medicine and Health Sciences, Faculty of Medicine and Health Sciences , Linköping University , Linköping , Sweden., Dimberg J; c Department of Natural Science and Biomedicine, School of Health and Welfare , Jönköping University , Jönköping , Sweden., Geffers R; d Genome Analytics, Helmholtz Centre for Infection Research , Braunschweig , Germany., Wågsäter D; b Division of Drug Research, Department of Medicine and Health Sciences, Faculty of Medicine and Health Sciences , Linköping University , Linköping , Sweden. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer investigation [Cancer Invest] 2019; Vol. 37 (2), pp. 99-112. Date of Electronic Publication: 2019 Mar 05. |
| DOI: | 10.1080/07357907.2019.1576191 |
| Abstrakt: | Platelet-derived growth factor D (PDGF-D) has been shown to mediate cellular processes of importance in cancer progression. This study aimed to investigate the expression and putative involvement of PDGF-D signaling in colorectal carcinogenesis. PDGF-D was expressed in vascular endothelial cells in tumor and normal tissues. PDGF-D stimulation of cells altered genes of importance in carcinogenic processes. In addition, PDGF-D increased the proliferation rate while imatinib inhibited these effects. PDGF-D and its PDGF receptor beta (PDGFR-β) are expressed in colorectal cancer and blockage of PDGF-D/PDGFR-β signaling using tyrosine kinase inhibitors, such as imatinib, might be important in inhibiting tumor-promoting actions. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|